A breast cancer liquid biopsy is a quick and painless substitute for surgical biopsies that enables doctors to learn many details about a tumor from just one blood sample. Moreover, liquid biopsy for breast cancer patients may enhance treatment and clinical results. Due to advances in technology and medicinal therapy, liquid biopsy for breast cancer is very fragmented.
In 2021, the market value of breast cancer liquid biopsy was worth USD 124.46 million, and by 2030 it will reach USD 604.71 million, growing at a 19.2% CAGR during the forecast period.
The market is driven by factors like the rising incidence of breast cancer cases, rising demand for minimally invasive procedures, rising cancer awareness, rising healthcare costs, and initiatives taken by the government and international health organizations. Moreover, the market will grow due to more intensive cancer research and development, technology developments, and a rise in demand for individualized therapy.
Market Dynamics
Drivers
The primary factor boosting market growth is the increasing rate of breast cancer in the general population. For instance, according to the WHO, in 2020, nearly 2.3 million women were diagnosed with breast cancer causing 685,000 deaths globally. One of the most common applications of liquid biopsy is a breast cancer diagnosis, which employs mutational analysis to select the most effective targeted treatment. For instance, determining the next stage of treatment for patients with metastatic sickness can be assisted by screening for the PIK3CA mutation, which is present in about 40% of all HR-positive breast tumors.
Increased initiatives from major market players will fuel expansion over the forecast period. Several businesses are launching steps to expand the use of biopsies globally, which is accelerating growth.
Restraints
The development of the market is severely constrained by the lack of accessibility to and awareness of breast cancer in developing nations. Also, there is a shortage of qualified doctors, and late-stage diagnosis occurs occasionally.
Opportunity
Due to technological developments in the field of ongoing research on circulating biomarkers, a less intrusive way of diagnosing non-hematological tumors has been create. A growing number of people are becoming aware of the clinical significance of liquid biopsy due to ongoing developments in related fields. Further interventional clinical trials are require, combine with the creation of an algorithm to combine the right circulating biomarkers to make these technologies widely accessible. The commercialization of such tests in the following years will simplify the detection of the ailment. According to John Hopkins Medical in June 2022, liquid biopsy can detect advanced breast cancer biomarkers in 5 hours.
Market Segmentation
By Circulating Biomarkers
In 2021, the circulating cell-free DNA (cfDNA) segment ruled the entire market. It is due to the ability of cfDNA to diagnose recurrence or progression, detect growing genomic anomalies linked to drug resistance, and track tumor molecular profiles in real time.
The circulating tumor cell will expand rapidly during the forecast period. It is due to the capacity of CTCs to provide increased sensitivity as biomarkers for early cancer diagnosis. With larger CTCs counts attributed to a very high risk of getting cancer.
By Application
In 2021, the treatment selection segment was the market leader. With a significant revenue share due to the requirement for early treatment. The relevance of early identification, characterization. And management of breast cancer in its early stages has increased due to the development of liquid biopsies to improve. The likelihood of effective therapy selection and improved prognosis.
Regional Analysis
North America was the biggest regional market in 2021. This is due to rapid technological development, the use of liquid biopsies in treatment decision-making, and expanding government initiatives. Due to higher investments and numerous biotechnology businesses developing the test, the U.S. dominates the North American market.
Over the forecast period, Asia Pacific will see profitable growth. It is due to the expanding population, the growing need for services, and the emergence of major market players. There is a larger population base and a growing cancer rate in the Asia Pacific region. According to Global Cancer Statistics 2020, Asia Pacific was home to nearly 58.3% of cancer deaths. And approximately half of all cancer incidences in 2020.
Key Players
- Qiagen
- Guardant Health Inc.
- Biocept Inc
- Hoffmann-La Roche Ltd
- Janssen Diagnostics
- Myriad Genetics
- Johnson & Johnson
- Biodesix
- Fluxion Biosciences Inc.
- Illumina Inc.
- Adaptive Biotechnologies
In 2021, the market value of breast cancer liquid biopsy was worth USD 124.46 million. And by 2030 it will reach USD 604.71 million, growing at a 19.2% CAGR during the forecast period. The market growth is accelerate by the increasing rate of breast cancer. Increased awareness of early diagnosis and treatment, and a greater desire for non-invasive procedures.
The treatment determination section held the biggest income share in 2021, ascribed to the need to give early treatment. Fluid biopsies have arisen as a fundamental apparatus for upgrading the significance of early identification, portrayal, and the board of bosom disease in the beginning phases which makes this clinical setting the most suitable to build the opportunities for powerful treatment choice and further developed visualization.
Related Reports:
Green Hydrogen Market Report – The global green hydrogen market will witness a robust CAGR of 55.1%, valued at $1.45 billion in 2021, expected to appreciate and reach $75.72 billion by 2030, confirms Strategic Market Research. Europe had the highest share of the worldwide green hydrogen market, with more than 57%.
